DPP4 and hydrops fetalis: A meta-analysis of 23 cardiovascular outcome trials comparing the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RA), SGLT2 inhibitors, and dipeptidyl peptidase-4 (DPP-4) inhibitors showed a superior reduction in HF hospitalizations and mortality by SGLT2 [108].